Scaling new heights in the fight against heart disease
We are focused on advancing our clinical-stage lead gene therapy programs, TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated ARVC.
We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver potentially curative therapies that address the underlying drivers of heart disease.
Founded by leading cardiovascular scientists, our team has the tenacity to pursue our ultimate peak – changing the treatment paradigm for heart disease, and in doing so improving and extending the lives of millions of individuals and families fighting these debilitating conditions.
LATEST NEWS
Tenaya Therapeutics Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the
Read MoreTenaya Therapeutics Announces Proposed Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it
Read MoreTenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a
Read More
PATIENTS FIRST
Here at Tenaya, we strive to make the needs of patients our top priority in all we do. As we develop new medicines aimed at targeting the genetic underpinnings of cardiomyopathies, we’ve sought input from patients and their families all along the way to better understand how genetic conditions like hypertrophic cardiomyopathy and arrhythmogenic right ventricular impact their lives daily and over time. We’ve also created resources to help patients, their families and their physicians better understand how gene therapies work and what to expect from our clinical trials.